LOGO.png
Autolus Therapeutics announces publication of new AUTO6 Phase 1 data in childhood neuroblastoma in Science Translational Medicine
30 nov. 2020 07h00 HE | Autolus Therapeutics plc
- Findings from the Phase 1 study provide evidence that AUTO6 induces clinical activity in this solid tumor setting without inducing on-target off-tumor toxicity - AUTO6NG builds on this approach...
Autolus Therapeutics and Noile-Immune Announce Licensing Agreement
13 nov. 2019 06h30 HE | Autolus Therapeutics plc
LONDON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, and Noile-Immune...
Autolus Therapeutics Presents Preclinical Data on AUT06NG at the SITC Annual Meeting
09 nov. 2019 07h00 HE | Autolus Therapeutics plc
LONDON, Nov. 09, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment...
Autolus Announces Data Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
03 oct. 2019 09h08 HE | Autolus Therapeutics plc
LONDON, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
provectus_logo.jpg
Article on anti-tumor activity of PV-10 against relapsed and refractory neuroblastoma published in OncoTargets and Therapy
19 févr. 2019 07h30 HE | Provectus Biopharmaceuticals Inc.
Provides preclinical proof-of-concept data on efficacy of single-agent PV-10 for treatment of neuroblastomaSupports use of checkpoint inhibitors with PV-10 treatment backbone to further enhance...
provectus_logo.jpg
US FDA GRANTS PV-10 ORPHAN DRUG DESIGNATION FOR NEUROBLASTOMA
05 nov. 2018 08h00 HE | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company was granted orphan drug designation (ODD) by the U.S. Food and Drug Administration (FDA)...
First-Time Team RMHC Marathon Runner Dedicates 2011 Chicago Marathon to Eight-Year-Old Son Battling Cancer
06 oct. 2011 11h00 HE | Ronald McDonald House Charities Global
OAK BROOK, IL--(Marketwire - Oct 6, 2011) - Running a marathon is a challenge; both physically and mentally, but to Mark Johnston, it's nothing compared to the race his son Luke has been running...